# Biosimilar Switching in Dermatology

## FDA-Approved Biosimilars (as of 2025)
### Adalimumab (Humira) Biosimilars
- Amjevita (adalimumab-atto)
- Hyrimoz (adalimumab-adaz)
- Cyltezo (adalimumab-adbm)
- Hadlima (adalimumab-bwwd)
- Abrilada (adalimumab-afzb)

## Clinical Evidence
- 94% maintain PASI response after biosimilar switch
- No increased adverse events vs reference product
- Interchangeability: Some FDA-designated as interchangeable
- Cost savings: 30-50% reduction vs reference product

## Switching Indications
1. Formulary optimization (non-medical switch)
2. Patient cost burden reduction
3. Loss of efficacy (possible antibody formation)

## Contraindications to Switching
- Active disease flare
- Recent switch (<6 months)
- Patient unwillingness despite education
